News and press

Filter by:

7th January 2013

A genomic portrait of the emergence, evolution and global spread of a methicillin-resistant Staphylococcus aureus pandemic

The widespread use of antibiotics in association with high-density clinical care has driven the emergence of drug-resistant bacteria that are adapted to thrive in hospitalized patients.

Matthew T.G. Holden, Li-Yang Hsu, Kevin Kurt, Lucy A. Weinert, Alison E. Mather, Simon R. Harris, Birgit Strommenger, Franziska Layer, Wolfgang Witte, Herminia de Lencastre, Robert Skov, Henrik Westh, Helena Žemličková, Geoffrey Coombs, Angela M. Kearns, Robert L.R. Hill, Ian Gould, Vanya Gant, Jonathan Cooke, Giles F. Edwards, Paul R. McAdam, Kate E. Templeton, Angela McCann, Zhemin Zhou, Santiago Castillo-Ramírez, Edward J., Lyndsey O. Hudson, Mark C. Enright, Francois Balloux, David M. Aanensen, Brian G. Spratt, J. Ross Fitzgerald, Julian Parkhill, Mark Achtman, Stephen D. Bentley, Ulrich Nübel

3rd January 2013

Selection for qacA carriage in CC22 but not CC30 MRSA bloodstream infection isolates during a successful institutional infection control programme.

The increasing use of chlorhexidine for methicillin-resistant Staphylococcus aureus (MRSA) decolonization raises concerns about reduced susceptibility.

Otter JA, Patel A, Cliff PR, Halligan EP, Tosas O

1st January 2013

Urinary steroid profiling

4th December 2012

Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia.

To determine the utility of secondary stratification measures to improve the ascertainment of index cases of familial hypercholesterolaemia (FH).

Rosemary E J Clarke , Soundrie T Padayachee, Rebecca Preston, Zofia McMahon, Mitchell Gordon, Colin Graham, Martin A Crook, Professor Anthony S. Wierzbicki

3rd December 2012

U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.

Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors

J.J. Scarisbrick, S. Morris, R. Azurdia, T. Illidge, E. Parry, R. Graham-Brown, R. Cowan, E. Gallop-Evans, R. Wachsmuth, M. Eagle, Professor Anthony S. Wierzbicki, H. Soran, S. Whittaker, E.M. Wain

19th November 2012

Strategy for the creation of clinical grade hESC line banks that HLA-match a target population

Here, we describe a pre-derivation embryo haplotyping strategy that we developed in order to maximize the efficiency and minimize the costs of establishing banks of clinical grade hESC lines in which human leukocyte antigen (HLA) haplotypes match a significant proportion of the population.

Jacquet L, Stephenson E, Collins R, Patel H, Trussler J, Al-Bedaery R, Renwick P, Ilic D

6th November 2012

Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency.

Homozygous lipoprotein lipase (LPL) deficiency is an ultra-orphan disease associated with increased rates of pancreatitis.

Professor Anthony S. Wierzbicki, Viljoen A

9th October 2012

The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia.

The dramatic improvements seen in the outcome of paediatric patients with acute lymphoblastic leukaemia (ALL) have led to increasing incorporation of L-asparaginase (L-Asp) in adult treatment protocols.

E Truelove, A K Fielding, Professor Beverley Hunt

11th September 2012

Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial.

To examine whether the effect of tranexamic acid on the risk of death and thrombotic events in patients with traumatic bleeding varies according to baseline risk of death.

Ian Roberts , Pablo Perel, David Prieto-Merino, Haleema Shakur, Tim Coats, Professor Beverley Hunt, Fiona Lecky, Karim Brohi, Keith Willett

23rd August 2012

Nonalcoholic fatty liver disease and lipids.

This article reviews the mechanisms leading to the development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) and the effects of hypoglycaemic and lipid-lowering therapies on NAFLD/NASH.

Professor Anthony S. Wierzbicki, Oben J

Last updated: 23/09/2022

Search form

News and press

eMail alerts and news

Site details

Search form

News and press

Share this page

eMail alerts and news

Follow us

Site details